The in vitro activity of a new oral antimicrobial agent, norfloxacin (MK-0366), was compared with those of nalidixic acid, nitrofurantoin, co-trimoxazole, trimethoprim, sulfamethoxazole, cinoxacin, tetracycline, ampicillin, carbenicillin, and cephalexin against 628 urinary bacterial isolates. Norfloxacin was the most active antimicrobial agent tested against the gram-negative bacilli. It was less active than a few of the other antimicrobial agents against enterococci and Staphylococcus aureus.
Norfloxacin (MK-0366 or AM-715) is an antibacterial organic acid structurally related to nalidixic acid. Unlike nalidixic acid, norfloxacin exhibits a very broad spectrum of antibacterial activity against both gram-positive and gramnegative bacteria, including Pseudomonas aeruginosa and Serratia marcescens (2). In experimental systemic and urinary bladder-kidney infections in mice, norfloxacin was found to be five times as active as pipemidic acid and nalidixic acid (1). This study was the most active antimicrobial agent tested against all of the above-named organisms. Cotrimoxazole and trimethoprim were the next most active antimicrobial agents against the Enterobacteriaceae. Against P. aeruginosa, norfloxacin inhibited 90% of the isolates at a concentration of 4 ,ug/ml, whereas all of the other antimicrobial agents inhibited 90% of the isolates at concentrations of >128 ,ug/ml.
Against the gram-positive cocci, norfloxacin inhibited 90% of enterococci at 8 ,ug/ml, 90% of S. aureus at 4 jxg/ml, and 90% of S. epidermidis at 2 ,g/ml. It was the most active antimicrobial agent tested against S. epidermidis. However, ampicillin, co-trimoxazole, and trimethoprim were more active than norfloxacin against enterococci. Co-trimoxazole and trimethoprim were also more active than norfloxacin against S. aureus. Norfloxacin was not as active against gram-positive cocci as it was against gram-negative bacilli.
Recently Clayman, and J. Warren, 21st ICAAC, abstr. no. 566). As with our study, all found norfloxacin to be consistently more active than the oral antimicrobial agents currently available for use in the treatment of urinary tract infections. After a single oral dose of 800 mg, peak serum levels of norfloxacin approach 2.5 ,ug/ml, with a halflife of more than 4 h. Urinary concentrations under these conditions exceed 350 ,ug/ml (H. H. Gadebusch, Merck Sharp & Dohme, personal communication) . This level in the urine is many times greater than the MIC of norfloxacin for all of the urinary isolates tested in our study. A preliminary report from Japan has shown that norfloxacin is effective in the treatment of urological infections in humans (Y. Nishimura, H. Kishi, 0. Tsukada, T. Tominaga, and T. Niijima, 20th ICAAC, New Orleans, La., abstr. no. 76, 1980) . In summary, our in vitro results demonstrate that norfloxacin is highly active against urinary tract bacterial pathogens. Clinical trials to verify its efficacy as an oral antimicrobial agent for urinary tract infections are indicated.
